Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology - 1 Jan 2023

Liu Jiewei, Cheng Yuqi, Li Ming, Zhang Zhijun, Li Tao, Luo Xiong-Jian

Abstract excerpt

Psychiatric disorders impose tremendous economic burden on society and are leading causes of disability worldwide. However, only limited drugs are available for psychiatric disorders and the efficacy of most currently used drugs is poor for many patients. To identify novel therapeutic targets for psychiatric disorders, we performed genome-wide Mendelian randomization analyses by integrating brain-derived...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genome-Wide Association Study
Share to HLA-DRB1 Chains

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mendelian Randomization Analysis

Share to Mental Disorders

Share to Polymorphism, Single Nucleotide

Share to Proteasome Endopeptidase Complex

Share to Proteome

Share to Proteomics

Source

Open in PubMed Open full text

Identifiers

PMID: 36114287
DOI: 10.1038/s41386-022-01456-5
PMCID: PMC9483418

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders.PMID 36114287Read ↗

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.Semantic proximity Read ↗

Uncovering bi-directional causal relationships between plasma proteins and psychiatric disorders: A proteome-wide study and directed network analysisSemantic proximity Read ↗

Dissecting the shared genetic landscape of anxiety, depression, and schizophrenia.Semantic proximity Read ↗

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read ↗

Causal effects of lipid-lowering drug targets on psychiatric disorders: A drug-target Mendelian randomization study.Semantic proximity Read ↗

Convergent proteogenomic evidence prioritises five causal proteins and new drug targets for major psychiatric disordersSemantic proximity Read ↗

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read ↗

Identifying therapeutic target genes for migraine by systematic druggable genome-wide Mendelian randomization.Semantic proximity Read ↗

Circulating Proteins Influencing Psychiatric Disease: A Mendelian Randomization Study.Semantic proximity Read ↗

Genetically informed drug target prioritisation and repurposing for major depressive disorderSemantic proximity Read ↗

Pharmaceutical Repurposing Strategies for Metabolic Disorders: Insights from Mendelian Randomization StudiesSemantic proximity Read ↗

Mendelian randomization analysis of the brain, cerebrospinal fluid, and plasma proteome identifies potential drug targets for attention deficit hyperactivity disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.